Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline2022년 6월 업데이트: 코로나바이러스 질병 2019(COVID-19)로 입원한 성인 관리: 유럽 호흡기 학회 생활 지침Editorial Published on 2022-08-102022-09-11 Journal: The European Respiratory Journal [Category] Fulltext, SARS, 바이오마커, [키워드] anti-IL-6 anticoagulation Baricitinib coronavirus disease Corticosteroids COVID-19 guideline European hospitalised hospitalised patient Hospitalised patients management monoclonal antibodies Non-invasive respiratory support recommendation respiratory Society with COVID-19 [DOI] 10.1183/13993003.00803-2022 PMC 바로가기 [Article Type] Editorial
Diagnostic yield of screening for SARS-CoV-2 among patients admitted to hospital for alternate diagnoses: an observational cohort studyObservational Study Published on 2022-08-102022-10-04 Journal: BMJ Open [Category] SARS, 임상, [키워드] 95% CI addition average Canada Care clinically suspected Contact COVID-19 COVID-19 cases Department determine diagnose Diagnosis diagnostic Diagnostic microbiology eligible adult Emergency enrolled Epidemiology Factor Fever Health services healthcare worker hospital hospitalised hospitalised patient identify network nucleic acid amplification Observational cohort study Organisation of health services pandemic Patient patients positive Positive test Prevalence Rapid response resulting risk risk factor SARS-CoV-2 tested Universal [DOI] 10.1136/bmjopen-2021-057852 PMC 바로가기 [Article Type] Observational Study
Should RECOVERY have used response adaptive randomisation? Evidence from a simulation studyRandomized Controlled Trial Published on 2022-08-062022-10-04 Journal: BMC Medical Research Methodology [Category] SARS, 임상, [키워드] adaptive adaptive randomisation Adaptive trial Arm ARMS Care Community coronavirus COVID-19 COVID-19 mortality COVID-19 therapy defined Dexamethasone effective error rate estimate exhibiting FIVE fixed form hospitalised Hydroxychloroquine induce Lopinavir-ritonavir lower mortality Measures mortality rate other diseases Patient patient death patient subgroup performed Platform trial question randomisation randomised controlled trial Randomised Evaluation receiving recovery RECOVERY trial reduced reducing reduction REMAP-CAP representing Respiratory Support Response-adaptive randomization Simulation standard care Statistical power tested Treatment Trial Two-arm [DOI] 10.1186/s12874-022-01691-w PMC 바로가기 [Article Type] Randomized Controlled Trial
Risk Factors for Slow Viral Decline in COVID-19 Patients during the 2022 Omicron Wave2022년 오미크론 파동 동안 COVID-19 환자의 느린 바이러스 감소에 대한 위험 요소Article Published on 2022-08-042022-09-11 Journal: Viruses [Category] SARS, 변종, [키워드] Adult patients age Analysis Chronic kidney disease conducted COVID-19 Ct value Decline declined delta variant determine Factor Geriatrics highest hospitalised hyperlipidaemia hypertension independent risk factor Isolation Kidney disease Kinetics knowledge lowest Multivariate analysis Older age omicron Omicron variant Patient PSO remained retrospective cohort study risk factor Risk factors SARS-CoV-2 SARS-CoV-2 viral SARS-CoV-2 viral shedding slow statistically significant termination the timing Univariate analysis vaccination variant Viral load viral shedding Wave [DOI] 10.3390/v14081714 PMC 바로가기 [Article Type] Article
Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trialRandomized Controlled Trial Published on 2022-08-042022-10-04 Journal: The European Respiratory Journal [Category] Fulltext, SARS, 임상, [키워드] 1:1 28-day mortality 95% CI age assigned Clinical improvement clinical status clinical trial Controlled trial coronavirus disease COVID-19 death demonstrated Dexamethasone discharged Effect Efficacy enrolled Evidence High dose High-dose high-dose group hospitalised hospitalised COVID-19 patient hospitalised patient low dose low-dose male moderate no significant difference Open-label outcome oxygen Oxygen therapy Patient performed Pneumonia Primary outcome randomisation randomised Randomly receive reduced secondary seven-point ordinal scale severe COVID-19 Time to recovery worsening [DOI] 10.1183/13993003.02518-2021 PMC 바로가기 [Article Type] Randomized Controlled Trial
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trialClinical Trial Published on 2022-08-012022-10-05 Journal: The Lancet. Haematology [Category] Coronavirus, Fulltext, MERS, 임상, [키워드] 1:1 105 patient 105 patients adverse event adverse events all-cause mortality analysed Asian assigned Belgium benefit black bleeding event Brazil Clinical practice Complete country COVID-19 COVID-19 vaccine death died dose Efficacy and safety eligibility eligible participant enrolled enrolment evaluate event rate FIVE Follow-up had no hazard ratio hospitalisation hospitalised in both group increased risk India Inflammation intention-to-treat population International IQR main analysis men middle multicentre no difference non-critically ill patient one patient Open-label Outpatient participant Patient patients with COVID-19 Pneumonia primary efficacy endpoint Prophylactic Prophylaxis random randomisation randomised Randomly receive Registered risk factor Safety Safety Monitoring Board Sanofi severe disease severity Sex similar studies South Africa Spain Standard of care Standard-of-care symptom onset symptomatic thromboembolic complications Trial uterine bleeding was done weighed were assessed white with COVID-19 women [DOI] 10.1016/S2352-3026(22)00173-9 PMC 바로가기 [Article Type] Clinical Trial
Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titresCOVID-19에 대한 회복기 혈장: 높은 중화 항체 역가와 관련된 기증자 인구 통계학적 요인Article Published on 2022-08-012022-09-11 Journal: Transfusion medicine (Oxford, England) [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] antibody antibody level antibody levels Asian association Better clinical factor convalescent plasma COVID-19 COVID-19 pandemic demographic factor Donor donors ELISA England evaluated help high neutralising antibody hospitalised IgG antibodies IgG antibody less levels of antibodies male MOST multivariable logistic regression multivariable logistic regression model Older plasma predicted predictor Probability SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody SARS-COV-2 infection SARS-CoV-2 variants second wave supply tested therapeutic titre treatment for COVID-19 was used white with COVID-19 [DOI] 10.1111/tme.12868 PMC 바로가기 [Article Type] Article
Comparison of trends in Clostridioides difficile infections in hospitalised patients during the first and second waves of the COVID-19 pandemic: A retrospective sentinel surveillance studyResearch article Published on 2022-08-012022-10-05 Journal: The Lancet Regional Health - Europe [Category] 진단, [키워드] 95%CI adjusted Analysis caused CDI change Characteristics Clostridioides difficile Clostridioides difficile infection Complete COVID-19 COVID-19 pandemic Delayed diagnostics Epidemiology Factors finding FIVE funding hospital hospitalised hospitalised patient hygiene incidence rate nine Patient patients retrospective SARS-CoV-2 second wave social distancing Surveillance Symptoms trend [DOI] 10.1016/j.lanepe.2022.100424 [Article Type] Research article
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysisCOVID-19로 병원에 입원한 환자의 바리시티닙(RECOVERY): 무작위, 통제, 공개 라벨, 플랫폼 시험 및 업데이트된 메타 분석Meta-Analysis Published on 2022-07-302022-09-11 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 임상, [키워드] 1:1 28-day mortality 95% CI age-adjusted rate ratio allocation Baricitinib benefit by mouth cause Corticosteroid Corticosteroids COVID-19 COVID-19 therapy death deaths died discharge eight enrolled evaluate Evidence hospital hospitalised Including Infection inhibitor Innovation intention-to-treat population ISRCTN Jak JAK inhibitor jak inhibitors janus Janus kinase Medical Research Council Meta-analysis mouth nine Non-COVID-19 once daily Open-label outcomes Patient Platform trial Primary outcome Proportional reduction randomisation randomised randomised controlled trial Randomised Evaluation Randomly randomly assigned patient rate ratio receive receiving recorded recovery RECOVERY trial reduce mortality reduced reduction in mortality Registered risk of death significantly Standard of care suggested thrombosis Tocilizumab Treatment Trial trials usual care usual care alone usual care group was done with COVID-19 [DOI] 10.1016/S0140-6736(22)01109-6 PMC 바로가기 [Article Type] Meta-Analysis
Impact of a phone call with a medical student/general practitioner team on morbidity of chronic patients during the first French COVID-19 lockdown (COVIQuest): a cluster randomised trialRandomized Controlled Trial Published on 2022-07-282022-10-04 Journal: BMJ Open [Category] 임상, [키워드] 95% CI Admission approach chronic cardiovascular Chronic diseases Cluster Contact control group COVID-19 CVD disease disorder eight evaluate French healthcare hospitalisation hospitalised Impact intervention group lack lockdown mental health morbidity older patient outcome Patient Preventive medicine primary care randomised controlled trial Randomised trial reduce reduced regions risk significantly statistical the patient usual care [DOI] 10.1136/bmjopen-2021-059464 PMC 바로가기 [Article Type] Randomized Controlled Trial